Stivarga Filings Reinforce Bayer’s HCC Position, For Now
Executive Summary
Bayer has filed Stivarga for use in second-line advanced liver cancer, and is set to dominate this indication in the near future, although serious competition lies in wait.
You may also be interested in...
Liver Cancer: What's Close To The Market
The treatment of liver cancer will have a makeover in coming months, with several products including Bristol’s Opdivo nearing the market for a disease that is often diagnosed late and where previously there have been few meaningful advances in therapy for many years. Two recently published reports from Datamonitor Healthcare have reviewed the disease and the R&D pipeline for the condition.
Rydapt And Alunbrig Approvals Headline Good Week For Targeted Oncologics At US FDA
After almost 20 years, targeted therapy for oncology is still producing breakthroughs. This week saw two breakthrough-designated novel kinase inhibitor approvals, Novartis' Rydapt (midostaurin) and Takeda's Alunbrig (brigatinib), and breakthrough status for Pfizer's next-generation candidate lorlatinib.
Keeping Track: Mylan Submits Biosimilar Herceptin; FDA Clears Opdivo For Head And Neck Cancer
The latest drug development news and highlights from our FDA Performance Tracker.